Toe role of novel aggrecanase in rheumatoid arthritis and its diagnostic potential

新型蛋白聚糖酶在类风湿性关节炎中的作用及其诊断潜力

基本信息

  • 批准号:
    15390459
  • 负责人:
  • 金额:
    $ 9.6万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2003
  • 资助国家:
    日本
  • 起止时间:
    2003 至 2004
  • 项目状态:
    已结题

项目摘要

1 Expression analysis of novel aggrecanaseRNA was extracted from IL-1 b stimulated chondrosarcoma cells and chondrocytes and the aggrecanase expressions were analyzed by quantitative RT-PCR. When compared with fibroblasts, chondrosarcoma cells and chondrocytes showed higher induction of novel aggrecanase, thus indicating this novel aggrecanase is IL-1 induced specifically in cartilage cells. When chondrosarcoma cells were stimulated with IL-1b and TNFa, novel aggrecanase induced synergistically.2 Antibody against novel aggrecanaseWe raised a polyclonal antibody against novel aggrecanase, and checked its specificity by Western blotting. A novel aggrecanase was induced by IL-1b stimulation by Western blot analysis.3 KO mouseWe got hetero mice4 Signal mechanism for novel aggrecanase inductionMAP kinase inhibitor(PD98059,SB203580) were added to IL- 1b stimulated chondrosarcoma cells and the signaling pathway was determined.
1新型聚集蛋白聚糖酶的表达分析从IL-1 B刺激的软骨肉瘤细胞和软骨细胞中提取RNA,用定量RT-PCR分析聚集蛋白聚糖酶的表达。当与成纤维细胞相比时,软骨肉瘤细胞和软骨细胞显示出更高的新型聚集蛋白聚糖酶的诱导,从而表明这种新型聚集蛋白聚糖酶是IL-1在软骨细胞中特异性诱导的。当软骨肉瘤细胞用IL-1b和TNF α刺激时,新型聚集蛋白聚糖酶协同诱导。2针对新型聚集蛋白聚糖酶的抗体我们提出了针对新型聚集蛋白聚糖酶的多克隆抗体,并通过Western blotting检测其特异性。Western blot分析IL-1b刺激诱导的一种新型聚集蛋白聚糖酶。3 KO小鼠获得异种小鼠4新型聚集蛋白聚糖酶诱导的信号机制将MAP激酶抑制剂(PD 98059,SB 203580)加入IL- 1b刺激的软骨肉瘤细胞中,检测其信号通路。

项目成果

期刊论文数量(23)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
ADAMTS9 is inducible by IL-1beta and TNF-alpha in OUMS-27 chondrosarcoma cells and in human chondrocytes.
在 OUMS-27 软骨肉瘤细胞和人软骨细胞中,ADAMTS9 可被 IL-1β 和 TNF-α 诱导。
Dynamic induction of ADAMTS1 gene in the early phase of acute myocardial infarction
  • DOI:
    10.1093/jb/mvh138
  • 发表时间:
    2004-10-01
  • 期刊:
  • 影响因子:
    2.7
  • 作者:
    Nakamura, K;Hirohata, S;Shiratori, Y
  • 通讯作者:
    Shiratori, Y
Lp3/Hapln3, a novel link protein that co-localizes with versican and is coordinately up-regulated by platelet-derived growth factor in arterial smooth muscle cells
  • DOI:
    10.1016/j.matbio.2004.07.001
  • 发表时间:
    2004-08-01
  • 期刊:
  • 影响因子:
    6.9
  • 作者:
    Ogawa, H;Oohashi, T;Ninomiya, Y
  • 通讯作者:
    Ninomiya, Y
Suppression of chondrosarcoma cells by 15-deoxy-Delta(12,14)-prostaglandin J(2) is associated with altered expression of Bax/Bcl-xL and p21.
15-脱氧-Delta(12,14)-前列腺素 J(2) 对软骨肉瘤细胞的抑制与 Bax/Bcl-xL 和 p21 表达的改变有关。
Komatsubara I: "Spatially and temporally different expression of osteonectin and osteopontin in the infarct zone of experimentally induced myocardial infarction in rats."Cardiovasc Pathol. 12・4. 186-194 (2003)
Komatsubara I:“实验诱导的大鼠心肌梗塞的梗塞区骨连接蛋白和骨桥蛋白的空间和时间差异表达。”Cardiovasc Pathol 12・4(2003)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HIROHATA Satoshi其他文献

HIROHATA Satoshi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HIROHATA Satoshi', 18)}}的其他基金

The role of endocytosis in oateoarhthritis
内吞作用在骨关节炎中的作用
  • 批准号:
    26670665
  • 财政年份:
    2014
  • 资助金额:
    $ 9.6万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Regulatory mechanism of transcriptional factors and microRNA in arthritis
转录因子和microRNA在关节炎中的调控机制
  • 批准号:
    23390366
  • 财政年份:
    2011
  • 资助金额:
    $ 9.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Aggrecanase regulation system in osteoarthritis and strategy for early diagnosis and therapy for osteoarthritis
骨关节炎中聚集蛋白聚糖酶的调控系统及骨关节炎的早期诊断和治疗策略
  • 批准号:
    20390399
  • 财政年份:
    2008
  • 资助金额:
    $ 9.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Inducible mechanism and role of novel aggrecanase in early stage of arthritis and its therapeutic application
新型聚集蛋白聚糖酶在关节炎早期的诱导机制、作用及其治疗应用
  • 批准号:
    18390416
  • 财政年份:
    2006
  • 资助金额:
    $ 9.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Identifying new aggrecanase and producing antibody and gene-targeting mouse
鉴定新的聚集蛋白聚糖酶并产生抗体和基因靶向小鼠
  • 批准号:
    13470312
  • 财政年份:
    2001
  • 资助金额:
    $ 9.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
  • 批准号:
    MR/Y009681/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.6万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.6万
  • 项目类别:
    Research Grant
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 9.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
  • 批准号:
    491810
  • 财政年份:
    2023
  • 资助金额:
    $ 9.6万
  • 项目类别:
    Operating Grants
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
  • 批准号:
    EP/Y027760/1
  • 财政年份:
    2023
  • 资助金额:
    $ 9.6万
  • 项目类别:
    Fellowship
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
  • 批准号:
    10696749
  • 财政年份:
    2023
  • 资助金额:
    $ 9.6万
  • 项目类别:
Fibroblast-mediated inflammatory resolution of rheumatoid arthritis
成纤维细胞介导的类风湿性关节炎炎症消退
  • 批准号:
    10604629
  • 财政年份:
    2023
  • 资助金额:
    $ 9.6万
  • 项目类别:
A Potent D-peptide Inhibitor of TNFα for Treatment of Rheumatoid Arthritis
一种有效的 TNFα D 肽抑制剂,用于治疗类风湿性关节炎
  • 批准号:
    10822182
  • 财政年份:
    2023
  • 资助金额:
    $ 9.6万
  • 项目类别:
The roles and mechanisms of inflammation resolution in the development of Rheumatoid Arthritis
炎症消退在类风湿关节炎发展中的作用和机制
  • 批准号:
    10733789
  • 财政年份:
    2023
  • 资助金额:
    $ 9.6万
  • 项目类别:
Microbial metabolites impacting the response to methotrexate in rheumatoid arthritis
微生物代谢物影响类风湿性关节炎对甲氨蝶呤的反应
  • 批准号:
    10578433
  • 财政年份:
    2023
  • 资助金额:
    $ 9.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了